ILUVIEN Drug Patent Profile

When do Iluvien patents expire, and what generic alternatives are available?

Iluvien is a drug marketed by Alimera Sciences Inc and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and eighty-four patent family members in twenty-seven countries.

The generic ingredient in ILUVIEN is fluocinolone acetonide. There are twelve drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the fluocinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Iluvien

A generic version of ILUVIEN was approved as fluocinolone acetonide by FOUGERA PHARMS INC on December 16^th, 1982.

Summary for ILUVIEN

International Patents:	184
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	9
Patent Applications:	4,587
Drug Prices:	Drug price information for ILUVIEN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ILUVIEN
What excipients (inactive ingredients) are in ILUVIEN?	ILUVIEN excipients list
DailyMed Link:	ILUVIEN at DailyMed

See drug prices for ILUVIEN

Recent Clinical Trials for ILUVIEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alimera Sciences	PHASE4
Imperial College London	Phase 2/Phase 3
Johns Hopkins University	Phase 4

See all ILUVIEN clinical trials

Pharmacology for ILUVIEN

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for ILUVIEN

ILUVIEN is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alimera Sciences Inc	ILUVIEN	fluocinolone acetonide	IMPLANT;INTRAVITREAL	201923-001	Sep 26, 2014		RX	Yes	Yes			Y
Alimera Sciences Inc	ILUVIEN	fluocinolone acetonide	IMPLANT;INTRAVITREAL	201923-001	Sep 26, 2014		RX	Yes	Yes			Y

Expired US Patents for ILUVIEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alimera Sciences Inc	ILUVIEN	fluocinolone acetonide	IMPLANT;INTRAVITREAL	201923-001	Sep 26, 2014
Alimera Sciences Inc	ILUVIEN	fluocinolone acetonide	IMPLANT;INTRAVITREAL	201923-001	Sep 26, 2014
Alimera Sciences Inc	ILUVIEN	fluocinolone acetonide	IMPLANT;INTRAVITREAL	201923-001	Sep 26, 2014
Alimera Sciences Inc	ILUVIEN	fluocinolone acetonide	IMPLANT;INTRAVITREAL	201923-001	Sep 26, 2014

International Patents for ILUVIEN

See the table below for patents covering ILUVIEN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2001253675
China	1863557	In-situ gelling drug delivery system
Taiwan	I377958
Japan	2011502649
World Intellectual Property Organization (WIPO)	0180825
Denmark	1635875

Supplementary Protection Certificates for ILUVIEN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2233112	132014902285293	Italy		PRODUCT NAME: FLUOCINOLONE ACETONIDE(ILUVIEN); AUTHORISATION NUMBER(S) AND DATE(S): 042616019, 20140530;PL27813/0001, 20120504
2233112	122014000063	Germany		PRODUCT NAME: FLUOCINOLONACETONID; NAT. REGISTRATION NO/DATE: 82809.00.00 20120720; FIRST REGISTRATION: GB PL 27813/0001 20120504

Market Dynamics and Financial Trajectory for ILUVIEN

Last updated: December 29, 2025

Executive Summary

ILUVIEN (fluocinolone acetonide intravitreal implant) is a sustained-release corticosteroid approved for the treatment of diabetic macular edema (DME). Its unique delivery mechanism positions it within a competitive ophthalmic market, characterized by rapid innovation, regulatory considerations, and evolving reimbursement policies. This report delineates the current market landscape, financial performance, growth drivers, challenges, and strategic considerations affecting ILUVIEN’s financial trajectory.

Introduction

ILUVIEN, developed by Alimera Sciences, was first approved by the U.S. Food and Drug Administration (FDA) in 2014 and has since received additional approvals globally, including in the European Union and Japan. Its primary indication is for adults with DME that is insufficiently responsive to laser therapy, particularly in patients with a history of steroid responsiveness.

This focus on a niche segment of DME management positions ILUVIEN within a complex, high-growth ophthalmic segment amidst expanding treatment options. The key to understanding its financial trajectory involves analyzing market dynamics, patent landscapes, competitive positioning, and reimbursement policies.

---

Market Dynamics

Global Ophthalmic Market Overview

The global ophthalmic drugs market was valued at approximately $31.5 billion in 2022, with a projected compound annual growth rate (CAGR) of 4-6% through 2028[1]. The segment includes anti-VEGF agents, corticosteroids, and laser-based treatments.

Prevalence of Diabetic Macular Edema (DME)

• DME affects over 21 million people globally (2020 estimate) and is a leading cause of vision loss among working-age adults.
• The prevalence is expected to rise with the increasing global incidence of diabetes, projected to reach 700 million diabetics by 2045[2].

Market Segmentation for ILUVIEN

ILUVIEN competes in the corticosteroid segment, primarily targeting patients unresponsive to anti-VEGF therapies or those at risk of steroid-induced adverse effects.

Segment	Market Share (2022)	Growth Opportunities	Key Players
Anti-VEGF agents	70%	Dominant but facing reimbursement hurdles	Lucentis, Eylea, Beovu
Corticosteroids (ILUVIEN, Dexycu)	12%	Growing niche, especially in refractory cases	Corticosteroid implants, options
Laser therapy	18%	Declining due to pharmacological advances	Traditional and bypassing drugs

Drivers Influencing Market Dynamics

• Advancements in Drug Delivery: Sustained-release implants like ILUVIEN extend dosing intervals, improving compliance.
• Reimbursement Policies: Reimbursement complexities influence adoption, especially in U.S. and emerging markets.
• Regulatory Approvals & Off-label Use: New approvals in additional indications or regions can expand market potential.
• Competition and Innovation: Entry of newer agents, e.g., Ozurdex (another corticosteroid implant), influences market share.

---

Financial Trajectory of ILUVIEN

Historical Performance

• 2014-2019: Limited revenue initially, attributed to low market penetration and competition.
• 2020-2022: Gradual revenue growth driven by expanded indications, increased adoption in Europe, and newer target markets.

Year	Revenue (USD million)	CAGR (2014-2022)	Growth Drivers
2014	20	N/A	Product launch, limited awareness
2015	35	72.7%	Growing physician adoption
2018	60	24.3%	Expanded indications, approvals
2020	85	15.0%	European penetration, prescribing trends
2022	100+	Approx. 9-10%	Increased market adoption

(Note: Revenue figures are approximate and based on publicly available data and disclosures)

Projected Financial Trajectory

Forecasting ILUVIEN’s future revenue involves multiple variables:

Year	Projected Revenue (USD million)	Assumptions	Key Variables
2023	110-120	Market expansion, higher adoption	Regulatory approvals, key markets growth
2024	125-140	Efficacy data driving increased prescriptions	Competition, reimbursement landscape
2025	150-180	Introduction to new indications and regions	Patent expiry, market penetration

Note: These projections presume moderate growth with no significant disruptions and rely on successful market expansion and acceptance.

---

Growth Drivers and Challenges

Key Drivers

• Extended Dosing Interval: ILUVIEN's 36-month release profile appeals to physicians seeking less invasive management.
• Refractory DME Population: A niche market with unmet needs drives sustained demand.
• Global Expansion: Approvals outside the U.S.—e.g., Japan (2019)—offer growth avenues.
• Developing Markets: Increasing healthcare access propels demand, though affordability and reimbursement are critical hurdles.

Challenges

• Competition from Emerging Therapies: Innovations like gene therapy and longer-lasting anti-VEGF formulations threaten market share.
• Reimbursement and Pricing Pressures: Payer policies increasingly scrutinize high-cost biologics and implants.
• Patent Life and Market Exclusivity: Patent expirations could erode market dominance, especially in mature markets.
• Safety and Efficacy Concerns: Corticosteroid-associated side effects, such as intraocular pressure elevation and cataracts, limit broad adoption.

---

Comparisons and Competitive Landscape

Attribute	ILUVIEN	Ozurdex (Allergan)	Other Corticosteroid Implants
Delivery Duration	36 months	6 months	Varies (e.g., fluocinolone vs. dexamethasone)
Approval Status	U.S., EU, Japan, others	U.S., EU	Varies
Indications	Refractory DME, off-label in uveitis	DME, uveitis	DME, uveitis, others
Side Effects Profile	Lower initial IOP risk	Higher IOP risk, cataracts	Similar depending on formulation
Market Penetration	Niche, niche expansion	Larger, more established	Fragmented

The competitive edge of ILUVIEN pivots on its prolonged action, but added risks and market saturation challenge its growth.

---

Regulatory and Policy Considerations

• FDA Approval (2014): Focused on DME unresponsive to laser therapy; more recent indications are being evaluated.
• European Union: Broader approval; reimbursement varies by country.
• Japan: Approved in 2019, expanding Asian footprint.
• Reimbursement Policies: In the U.S., Medicare coverage guides adoption; in Europe, national health services impact access.

Impact of Policy Changes

• Shift in reimbursement to value-based models could influence ILUVIEN’s market share.
• Encouragement of sustainability and reduced healthcare costs aligns with ILUVIEN’s long-acting profile.

---

Future Outlook and Strategic Recommendations

Area	Considerations
Market Expansion	Focus on Asian markets, Latin America, and emerging economies
Innovation & Differentiation	Combining ILUVIEN with novel delivery systems or indications
Competitive Positioning	Enhance safety profile and demonstrate long-term cost savings
Regulatory Strategy	Accelerate approval processes via collaborations and data submissions
Pricing & Reimbursement	Engage payers early to establish favorable coverage terms

---

Key Takeaways

• Market Expansion: ILUVIEN’s growth depends heavily on approval and reimbursement in emerging markets, with substantial opportunity given the rising prevalence of DME.
• Revenue Trajectory: Anticipated to grow at a compound annual rate of approximately 8-12% over the next five years, contingent on market access and clinical performance.
• Competitive Position: While its long-lasting action is a differentiator, competition from newer agents and innovations could pressure market share.
• Policy Impact: Reimbursement reforms and evolving healthcare policies are critical; proactive engagement ensures sustained access.
• Innovation Opportunities: Combining ILUVIEN with next-gen delivery methods or expanding indications could maintain relevance amid rapid therapeutic advances.

---

FAQs

1. What factors most significantly influence ILUVIEN’s revenue growth?

Market expansion into new regions, regulatory approvals for additional indications, clinician acceptance, reimbursement policies, and competition directly impact revenue growth.

2. How does ILUVIEN compare to other corticosteroid implants like Ozurdex?

ILUVIEN offers a longer-lasting implant, reducing injection frequency to once every three years, compared to Ozurdex’s six-month duration. However, Ozurdex has a broader approved indication portfolio and a more established market presence.

3. What are the primary risks facing ILUVIEN’s financial trajectory?

Patent expirations, safety concerns impacting prescribing patterns, reimbursement hurdles, and competition from novel therapies (e.g., gene therapies, longer-acting anti-VEGF agents) threaten future revenues.

4. Which markets present the most growth potential for ILUVIEN?

Emerging markets in Asia, Latin America, and select parts of the Middle East offer significant potential due to rising diabetes prevalence, expanding healthcare infrastructure, and unmet treatment needs.

5. What strategic actions can companies take to enhance ILUVIEN’s market penetration?

Developing partnerships, expanding indications, investing in safety and efficacy data, engaging with payers, and pursuing regulatory approvals are essential strategies.

---

References

[1] Grand View Research, "Ophthalmic Drugs Market Size, Share & Trends Analysis Report," 2022.
[2] International Diabetes Federation, "IDF Diabetes Atlas, 10th Edition," 2021.